Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Lactoferrin  COVID-19 treatment studies for Lactoferrin  C19 studies: Lactoferrin  Lactoferrin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 76% Improvement Relative Risk Recovery time -40% Time to viral- 39% primary c19early.org/lf Rosa et al. Lactoferrin for COVID-19 EARLY TREATMENT Is early treatment with lactoferrin beneficial for COVID-19? Retrospective 121 patients in Italy (October 2020 - March 2021) Faster viral clearance with lactoferrin (p=0.02) Rosa et al., J. Clinical Medicine, doi:10.3390/jcm10184276 Favors lactoferrin Favors control
Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study
Rosa et al., Journal of Clinical Medicine, doi:10.3390/jcm10184276
Rosa et al., Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study, Journal of Clinical Medicine, doi:10.3390/jcm10184276
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective survey based study in Italy with 82 patients treated with lactoferrin, and 39 control patients, showing significantly faster viral clearance with treatment. There was no significant difference in recovery time overall, however the treatment group had significantly more moderate condition patients (39% versus 8%), and improved recovery was seen with treatment as age increased. Median dose for asymptomatic patients was 400mg/day, for paucisymptomatic patients 600mg/day, and for moderate condition patients 1000mg three times a day.
risk of hospitalization, 75.6% lower, RR 0.24, p = 0.32, treatment 0 of 82 (0.0%), control 1 of 39 (2.6%), NNT 39, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 40.0% higher, relative time 1.40, p = 0.50, treatment 82, control 39, excluded in exclusion analyses: excessive unadjusted differences between groups.
time to viral-, 39.4% lower, relative time 0.61, p = 0.02, treatment 82, control 39, inverted to make RR<1 favor treatment, Cox regression, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rosa et al., 21 Sep 2021, retrospective, Italy, peer-reviewed, 8 authors, study period October 2020 - March 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperLactoferrinAll
Abstract: Journal of Clinical Medicine Article Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study Luigi Rosa 1, * , Giovanni Tripepi 2 , Enrico Naldi 3 , Marina Aimati 4 , Stefano Santangeli 5 , Francesco Venditto 6 , Marcello Caldarelli 7 and Piera Valenti 1 1 2 3 4 5 6 7 * Department of Public Health and Infectious Diseases, University of Rome “La Sapienza”, 00185 Rome, Italy; piera.valenti@uniroma1.it National Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, 89124 Reggio Calabria, Italy; gtripepi@ifc.cnr.it General Practitioner, 50136 Florence, Italy; enrico.naldi60@virgilio.it General Practitioner, 04011 Aprilia, Italy; marina.aimati@gmail.com General Practitioner, Barberino del Mugello, 50031 Florence, Italy; dott.santangeli@alice.it General Practitioner, 50124 Florence, Italy; fravend@katamail.com General Practitioner, 00178 Rome, Italy; studio.drcaldm@gmail.com Correspondence: luigi.rosa@uniroma1.it; Tel.: +39-06-4991-4543 A. Martín-Acebes Abstract: SARS-CoV-2, an enveloped, single-stranded RNA virus causing COVID-19, exerts morbidity and mortality especially in elderly, obese individuals and those suffering from chronic conditions. In addition to the availability of vaccines and the limited efficacy of the first dose of vaccine against SARS-CoV-2 variants, there is an urgent requirement for the discovery and development of supplementary antiviral agents. Lactoferrin (Lf), a pleiotropic cationic glycoprotein of innate immunity, has been proposed as a safe treatment combined with other therapies in COVID-19 patients. Here, we present a small retrospective study on asymptomatic, paucisymptomatic, and moderate symptomatic COVID-19 Lf-treated versus Lf-untreated patients. The time required to achieve SARS-CoV-2 RNA negativization in Lf-treated patients (n = 82) was significantly lower (p < 0.001) compared to that observed in Lf-untreated ones (n = 39) (15 versus 24 days). A link among reduction in symptoms, age, and Lf treatment was found. The Lf antiviral activity could be explained through the interaction with SARS-CoV-2 spike, the binding with heparan sulfate proteoglycans of cells, and the anti-inflammatory activity associated with the restoration of iron homeostasis disorders, which favor viral infection/replication. Lf could be an important supplementary treatment in counteracting SARS-CoV-2 infection, as it is also safe and well-tolerated by all treated patients. Received: 27 July 2021 Keywords: lactoferrin; COVID-19 patients; SARS-CoV-2   Citation: Rosa, L.; Tripepi, G.; Naldi, E.; Aimati, M.; Santangeli, S.; Venditto, F.; Caldarelli, M.; Valenti, P. Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study. J. Clin. Med. 2021, 10, 4276. https://doi.org/10.3390/ jcm10184276 Academic Editor: Miguel Accepted: 17 September 2021 Published: 21 September 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit